Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2005

01-08-2005 | Erratum

Erratum to: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study

Authors: Anna-Mária Tőkés, Janina Kulka, Sándor Paku, Ágnes Szik, Csilla Páska, Pál Kaposi Novák, László Szilák, András Kiss, Krisztina Bögi, Zsuzsa Schaff

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Excerpt

After publication of this work [1], it was brought to our attention that two corrections were required in the first table. First, the Claudin 1 forward and reverse primer sequences were the same. Second, the forward and reverse primer sequences of GAPDH were inversed. …
Literature
1.
Tőkés A-M, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res. 2005, 7: R296-R305. 10.1186/bcr983.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study
Authors
Anna-Mária Tőkés
Janina Kulka
Sándor Paku
Ágnes Szik
Csilla Páska
Pál Kaposi Novák
László Szilák
András Kiss
Krisztina Bögi
Zsuzsa Schaff
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1265

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue

Research article

Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer

Review

Imaging in breast cancer: Magnetic resonance spectroscopy

Research article

Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence

Research article

Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2

Review

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

Research article

Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits